Compare ICG & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICG | ICCC |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 88.9M |
| IPO Year | 2022 | 1995 |
| Metric | ICG | ICCC |
|---|---|---|
| Price | $1.43 | $11.49 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 282.3K | 6.6K |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.51 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $109.44 | N/A |
| P/E Ratio | ★ $6.80 | $21.08 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $0.60 | $4.52 |
| 52 Week High | $2.28 | $12.10 |
| Indicator | ICG | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 69.65 |
| Support Level | $1.41 | $9.47 |
| Resistance Level | $1.52 | $12.10 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 75.00 | 100.00 |
Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.